Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12589099 | Alpha-1062 for treating traumatic brain injury | 🖼🧊📄§ | 2026-03-31 | 2042-11-25 | 0 | 31 |
| 12589106 | Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier | 🖼🧊📄§ | 2026-03-31 | 2039-12-11 | 0 | 31 |
| 12589108 | Injectable bifunctional hydrogel with antibacterial activity as well as the preparative method and the use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-05-29 | 0 | 31 |
| 12589111 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | 🖼🧊📄§ | 2026-03-31 | 2041-11-24 | 0 | 31 |
| 12589112 | Oncolytic virus compositions including IL-15 complex and methods for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2041-01-22 | 0 | 31 |
| 12589118 | Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation | 🖼🧊📄§ | 2026-03-31 | 2038-08-28 | 0 | 31 |
| 12589117 | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases | 🖼🧊📄§ | 2026-03-31 | 2042-07-18 | 0 | 31 |
| 12589119 | Treatment of cachexia using fibroblast cells and products thereof | 🖼🧊📄§ | 2026-03-31 | 2039-11-04 | 0 | 31 |
| 12589120 | Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions | 🖼🧊📄§ | 2026-03-31 | 2042-10-12 | 0 | 31 |
| 12589123 | Compositions and methods comprising clostridium butyricum for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2041-04-20 | 0 | 31 |
| 12589131 | Use of collagen hydrolysate in prevention and/or treatment of food craving | 🖼🧊📄§ | 2026-03-31 | 2043-02-01 | 0 | 31 |
| 12589130 | Aloe extracts for microbial neutralisation | 🖼🧊📄§ | 2026-03-31 | 2043-04-19 | 0 | 31 |
| 12589141 | DNA vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-03-02 | 0 | 31 |
| 12589140 | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-01-22 | 0 | 31 |
| 12589142 | HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas | 🖼🧊📄§ | 2026-03-31 | 2040-06-02 | 0 | 31 |
| 12589143 | Human anti-PD-L1 peptide vaccines and methods of their use | 🖼🧊📄§ | 2026-03-31 | 2040-09-17 | 0 | 31 |
| 12589144 | Combined norovirus and rotavirus vaccine composition and methods of preparation | 🖼🧊📄§ | 2026-03-31 | 2041-01-06 | 0 | 31 |
| 12589146 | Adjuvanted protein vaccines comprising modified full-length spike protein of SARS-CoV-2 composition and methods of use | 🖼🧊📄§ | 2026-03-31 | 2043-02-22 | 0 | 31 |
| 12589151 | T cell modification | 🖼🧊📄§ | 2026-03-31 | 2039-11-29 | 0 | 31 |
| 12589149 | Method of modulating mucosal immunogenicity | 🖼🧊📄§ | 2026-03-31 | 2040-03-18 | 0 | 31 |
| 12589157 | Compositions of drug delivery agents and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2039-03-29 | 0 | 31 |
| 12589160 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2040-03-12 | 0 | 31 |
| 12589161 | PEGylated synthetic KL4 peptide, compositions and methods thereof | 🖼🧊📄§ | 2026-03-31 | 2040-07-10 | 0 | 31 |
| 12589162 | Trans-cyclooctene prodrug of monomethyl auristatin E | 🖼🧊📄§ | 2026-03-31 | 2041-08-06 | 0 | 31 |
| 12589165 | Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors | 🖼🧊📄§ | 2026-03-31 | 2038-04-11 | 0 | 31 |
| 12589166 | Compositions and methods for treating wounds | 🖼🧊📄§ | 2026-03-31 | 2041-05-13 | 0 | 31 |
| 12590093 | Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-09-27 | 0 | 31 |
| 12590063 | Phenol derivative | 🖼🧊📄§ | 2026-03-31 | 2041-09-03 | 0 | 31 |
| 12588679 | Systems, methods, and apparatuses for disinfection and decontamination | 🖼🧊📄§ | 2026-03-31 | 2043-03-21 | 0 | 31 |
| 12589147 | Multivalent HVT vector vaccine | 🖼🧊📄§ | 2026-03-31 | 2040-12-18 | 0 | 31 |
| 12589070 | Low-dosage orodispersible opioid tablet and method for preparing same | 🖼🧊📄§ | 2026-03-31 | 2040-08-13 | 0 | 31 |
| 12589136 | Viral vectors comprising RDH12 coding regions and methods of treating retinal dystrophies | 🖼🧊📄§ | 2026-03-31 | 2042-08-09 | 0 | 31 |
| 12590292 | Targeted T-cell therapy for treatment of multiple myeloma | 🖼🧊📄§ | 2026-03-31 | 2040-01-07 | 0 | 31 |
| 12590304 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | 🖼🧊📄§ | 2026-03-31 | 2040-05-21 | 0 | 31 |
| 12590335 | Targeted measure of transcriptional activity related to hormone receptors | 🖼🧊📄§ | 2026-03-31 | 2043-06-21 | 0 | 31 |
| 12590309 | Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy | 🖼🧊📄§ | 2026-03-31 | 2040-05-19 | 0 | 31 |
| 12589125 | Yogurt for regulating intestinal tract, preparation method therefor, and use thereof | 🖼🧊📄§ | 2026-03-31 | 2043-02-27 | 0 | 31 |
| 12590168 | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2044-01-23 | 0 | 31 |
| 12590123 | Compounds and methods for treating cancer, viral infections, and allergic conditions | 🖼🧊📄§ | 2026-03-31 | 2040-06-25 | 0 | 31 |
| 12590139 | MHC class II molecules and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-07-29 | 0 | 31 |
| 12590103 | Polymorph of EP4 receptor antagonist, preparation method therefor and use thereof | 🖼🧊📄§ | 2026-03-31 | 2041-01-29 | 0 | 31 |
| 12590157 | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments | 🖼🧊📄§ | 2026-03-31 | 2043-07-20 | 0 | 31 |
| 12589133 | Methods of downregulating CCL20 genes for treatment of traumatic brain injuries | 🖼🧊📄§ | 2026-03-31 | 2041-11-10 | 0 | 31 |
| 12590100 | Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-β-TrCP interaction for use in the treatment of fatty liver disease | 🖼🧊📄§ | 2026-03-31 | 2042-01-13 | 0 | 31 |
| 12590149 | Antibody and bispecific antibody targeting LAG-3 and use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-06-11 | 0 | 31 |
| 12589122 | Methods and compositions for treating infectious, autoimmune, and allergic disease | 🖼🧊📄§ | 2026-03-31 | 2039-11-05 | 0 | 31 |
| 12589092 | Polycyclic compound acting as kinase inhibitor | 🖼🧊📄§ | 2026-03-31 | 2041-01-11 | 0 | 31 |
| 12589121 | Method for obtaining occlusive biological dressing, occlusive biological dressing, use thereof and kit | 🖼🧊📄§ | 2026-03-31 | 2039-11-14 | 0 | 31 |
| 12589115 | Haematopoietic stem cell treatment | 🖼🧊📄§ | 2026-03-31 | 2039-03-29 | 0 | 31 |
| 12589085 | Use of diaminoguanidine derivative and feed composition thereof in preparation of veterinary drug | 🖼🧊📄§ | 2026-03-31 | 2039-07-22 | 0 | 31 |